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Abstract
Purpose Radiotherapy is the main therapeutic approach be-
sides surgery of localized prostate cancer. It relies on risk strat-
ification and exact staging. This report analyses the potential of
[68Ga]Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11), a new
positron emission tomography (PET) tracer targeting prostate-
specific membrane antigen (PSMA) for prostate cancer staging
and individualized radiotherapy planning.
Methods A cohort of 57 patients with prostate cancer scanned
with 68Ga-PSMA-11 PET/CT for radiotherapy planning was ret-
rospectively reviewed; 15 patients were at initial diagnosis and
42 patients at time of biochemical recurrence. Staging results of
conventional imaging, including bone scintigraphy, CT or MRI,
were compared with 68Ga-PSMA ligand PET/CT results and the
influence on radiotherapeutic management was quantified.
Results 68Ga-PSMA ligand PET/CT had a dramatic impact on
radiotherapy application in the presented cohort. In 50.8 % of
the cases therapy was changed.
Conclusion The presented imaging technique of 68Ga-PSMA
PET/CT could be a key technology for individualized radio-
therapy management in prostate cancer.
Keywords Prostate cancer . 68Ga-PSMA ligand PET/CT .
Radiotherapy planning . Individualized radiotherapy
Introduction
Radiotherapy plays an essential role in the curative treatment
of prostate cancer. While moderate doses of radiotherapy with
conventional techniques seem to result in slightly inferior re-
sults compared to radical surgery, modern technology has the
potential to overcome this limitation [1].
New strategies in the management of localized prostate
cancer incorporate more and more individualized approaches
based on innovative imaging to enable dose-escalated treat-
ment. Individualized approaches already start at the point of
diagnostic workup, where multiparametric prostate MRI has
shown the possibilities of identifying special regions at risk
and guiding biopsy. A recent investigation presented high de-
tection rates even when previous biopsies had been negative
[2]. Overall such a targeted diagnostic procedure resulted in a
higher percentage of cancer detection compared to classical
serial biopsy [3]. Generally MRI-guided biopsies are most
useful for improving the diagnosis of clinically significant
prostate cancers and reducing the diagnosis of clinically insig-
nificant cancers. Thus, overall there is usually only a minimal
overall increase in all prostate cancer detection.
The importance of exact imaging and staging of course
continues in the therapeutic decision-making to tailor the
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individual treatment of a patient. This goes beyond find-
ing stage IV patients; furthermore, modern techniques in
radiation oncology allow an individualized risk-adapted
therapy with high dose application to tumour lesions in
the prostate or in lymph nodes. Instead of treating the
entire prostate homogeneously, selective boosting of areas
bearing the most tumour cells has been proposed. These
ideas go back to the late 1990s, when a selective dose
escalation to intraprostatic tumour areas as detected in
MRI was shown to be feasible without increasing the dose
to organs at risk [4]. This specific targeting of the so-
called dominant intraprostatic lesion has been shown to
be dosimetrically feasible in confirmative publications
with doses up to 200 % of the regular therapeutic doses
[5, 6]. Using calculation models and tumour control prob-
abilities, this method in theory increases the therapeutic
ratio in selected patients [7]. Yet its efficacy in terms of
outcome still has to be proven. In analogy to this
intraprostatic approach, several groups have conducted
trials to selectively increase the dose in lymph node me-
tastases as opposed to giving a homogeneous dose to the
entire pelvis.
All these individualized approaches rely on the sensitivity
and the specificity of the underlying imaging modality. Since
conventional CToffers poor detection and differentiation pos-
sibilities here, the quest for a more precise and reliable tool has
a long history now. MRI approaches using ultrasmall particles
of iron oxide that are trapped in lymph nodes were used and
high sensitivity and specificity for detection of lymph node
metastases from 65 to 75 % and 93 to 96 % were reported [8].
11C-Choline positron emission tomography (PET) was
analysed with regard to the potential of finding the site of
relapse at biochemical relapse and showed a high detection
rate in 78% of their patients as demonstrated by Lépinoy et al.
[9]. Similar findings were reported by other groups enabling a
more individualized radiotherapy approach [10–12].
Intense overexpression of the cell surface peptidase
prostate-specific membrane antigen (PSMA) in the majority
of both primary and metastatic prostate cancers as well as a
positive correlation of PSMA with traditional adverse prog-
nostic factors makes this structure a promising target for mo-
lecular imaging [1, 2]. Using the novel 68Ga-labelled PSMA
ligand Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11),
which presents outstanding affinity to PSMA [13], a highly
selective approach of imaging prostate cancer, lymph node
metastases and distant metastases is available. This has been
shown to be possible in hybrid PET/CT and PET/MRI [14,
15]. Early reports found a better contrast than with choline
PET [16].
This study analyses the impact of PSMA-11 PET/CT on a
cohort of prostate cancer patients treated with radiotherapy




A total of 57 patients (Table 1) with prostate cancer were
retrospectively analysed with conventional CT and PSMA-
11 PET/CT imaging; 15 patients presented at initial diagnosis,
while 42 patients presented with recurrence after total prosta-
tectomy. The median age was 70 years (range 53–83) with a
median Gleason score of 8.0 (range 5–9) and a median
prostate-specific antigen (PSA) level of 3.0 ng/ml (range
0.16–113). According to the D’Amico criteria 22 patients
(38.6 %) had intermediate-risk and 31 patients (54.4 %)
high-risk cancer [19]. Table 1 displays the characteristics of
the examined patient cohort. It is possible that our cohort
presents some overlap with a previous analysis about the di-
agnostic accuracy of PSMA PET [16].
Imaging
PSMA-11 PET/CT
PET and CT imaging were performed for every patient on a
Biograph 6 PET/CT scanner (Siemens, Erlangen, Germany)
60±10min after intravenous injection of 68Ga-PSMA-11 (me-
dian 175 MBq, range 77–350). The target activity was 2–
3 MBq/kg body weight. Due to the short half-life of 68Ga
(68 min) only a wider range of injected activity than common-
ly seen with 18F tracers was achievable in the clinical
workflow; however, the shorter half-life simultaneously limits
radiation exposure. 68Ga-PSMA-11 was synthesized as previ-
ously described [13]. On conventional CT, lymph nodes were
regarded as pathologically involved if their short axis diameter
was ≥10mm. Lymph node involvement in 68Ga-PSMA ligand
PETwas diagnosed when a node on CT demonstrated a max-
imum standardized uptake value (SUVmax) >2. This cut-off
was chosen after evaluating the blood pool remainder at
60 min post-injection in the aorta, which was found to be a
mean SUVmax of 1.49±standard deviation of 0.49. Lymph
nodes were assessed as distant metastases if their localization
was beyond the true pelvis. TNM classification was per-
formed by two experienced readers in consensus. Lesions that
were visually considered as suggestive of prostate cancer were
counted and analysed in localization (local relapses, lymph
node, soft tissue and bone metastases) and SUVmax.
CT/MRI/bone scan
Additional imaging modalities were chosen depending on the
result of the preceding PSMA-11 PET/CT. If suspect bone
lesions were found, a bone scan was done as a second modal-
ity to confirm Btrue-positive^. All patients with primary tu-
mour inside the prostate additionally received multiparametric
Eur J Nucl Med Mol Imaging (2016) 43:34–41 35
MRI, otherwise only if PSMA-11 PET/CTwas suspicious for
local recurrence. MRI was focused on the prostate bed [T2-
weighted turbo spin echo (TSE) px 0.7×0.7 mm; repetition
time (TR) 9.0; echo time (TE) 97; T1-weighted TSE px
0.54×0.54 mm; TR 1.38; TE 11 post CM], but contained at
least one series covering the pelvis/abdomen. Dual-phase con-
trast-enhanced CT pelvis/abdomen was routinely performed
for radiation planning. PSMA-11 PET/low-dose CT and
contrast-enhanced CT were done within <3 weeks of each
other.
Results
In 12 of 57 (21.1 %) patients at least 1 lesion characteristic for
prostate cancer was detected in conventional CT. This includ-
ed ten patients at the time of recurrence and two patients with
initial diagnosis. According to the D’Amico criteria, two pa-
tients had low-risk, four intermediate-risk and six high-risk
cancer. Using 68Ga PSMA ligand PET/CT, 85 lesions charac-
teristic for prostate cancer were detected in 34 patients, 25
(73.5 %) patients with recurrence and 9 (26.5 %) at initial
diagnosis. Of 34 patients, 21 (61.7 %) had high-risk, 9
(26.5 %) intermediate-risk and 4 (11.6 %) low-risk cancer.
In 19 (32.8 %) patients no lesions were found with both
methods. Amongst the 85 lesions characteristic for prostate
cancer, 62 were defined as lymph node metastases, 9 as bone
metastases, 8 as local relapses and 6 as primary tumours.
The TNM staging of 29 of 57 (50.8 %) patients was
changed after PSMA-11 PET/CT imaging. This included 4
(13.7 %) patients with changes at initial diagnosis and 25
(86.3 %) patients at the time of recurrence. According to the
D’Amico criteria, 3 (10.3 %) patients with change in TNM
staging had low-risk, 11 (37.9 %) intermediate-risk and 15
(51.8 %) high-risk cancer. Of 29 patients, 15 (51.8 %) were
changed from N0 to N1, 9 patients (31.0 %) were changed
from M0 to M1a, 4 patients (13.8 %) were changed from M0
toM1b and 6 patients (20.7 %) were changed from Tx to T2a.
Within the group of high-risk patients, 15 of 31 (48.4 %)
were changed in TNM staging. Of 16 patients, 10 had no find-
ings in conventional CT and bone scan (Tx N0 M0). Four pa-
tients (26.7 %) were changed to N1 M0, three (20.0 %) to N0
M1a, two (13.3 %) to N1 M1a, two (13.3 %) to N1 M1b, two
(13.3 %) to T2a N0M0. One (6.7 %) patient was changed from
N1 M0 to N1 M1a and one (7.1 %) from N1 M1a to N1 M1b.
Of 22 patients among the group of patients with
intermediate-risk cancer, 11 (50.0 %) had a change in TNM
staging after PSMA-11 PET/CT. This included 9 of 11
(81.8 %) patients with changes fromN0 to N1, 3 patients from
M0 to M1a (27.3 %) and 1 patient from Tx to T2 (9.1 %).
Figure 1 illustrates the changes of TNM stage with respect to
the different imaging modalities.
Table 1 Patient characteristics of
the analysed cohort Characteristics All patients Initial diagnosis patients Recurrence patients
Age (years)
Median age (range) 70 (53–83) 69 (54–83) 70 (53–80)
Initial PSA level (ng/ml)
Median (range) 3.0 (0.16–113) 7.04 (0.28–45) 2.8 (0.16–113)
Initial Gleason score
Median (range) 8 (5–9) 8 (6–9) 8 (5–9)
MBq
Median (range) 175 (77–350) 168 (97–338) 176 (77–350)
Initial conventional TNM stage
Local relapses T1–3 2 1 1
Regional metastases N1 3 1 2
Soft tissue metastases M1a 3 1 2
Bone metastases M1b 5 0 5
None 45 12 31
TNM staging after PSMA
Local relapses T1–3 8 6 1
Regional metastases N1 16 3 13
Soft tissue metastases M1a 6 1 10
Bone metastases M1b 19 0 19
None 22 6 16
PSA level after radiotherapy
Median (range) 0.69 (0.02–11.4) 1.47 (0.06–6.3) 0.52 (0.02–11.4)
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The reported changes in TNM stage resulted in the follow-
ing alteration of radiotherapeutic management: based on
PSMA-11 PET/CT 29/57 patients (50.8 %) received a differ-
ent therapeutic approach compared to the initial plan based
upon conventional staging. Of 29 patients, 18 (62.1 %) re-
ceived an additional simultaneous integrated lymph node
boost due to a change from N0 to N1, while the extent of
pelvic lymphatic irradiation remained the same. Eight patients
(27.5 %) were changed fromM0 toM1a, which resulted in an
enlarged lymphatic field irradiation with either para-aortic
node region or inguinal node region plus an additional simul-
taneous integrated lymph node boost. Four patients (13.8 %)
were changed from M0 to M1b and radiotherapy was can-
celled and systemic therapy was given. Figures 2, 3 and 4
display cases at primary diagnosis and disease relapse in
which PSMA PET/CT changed the radiotherapeutic regimen.
Of the 16 PSMA-negative patients 5 had a PSA level <0.5,
8 had a PSA level between 0.51<1.0, 2 had a PSA level
between 1.1 and<2.0 and 1 patient had a PSA level of 21.7
and a Gleason score of 7.
Discussion
The presented analysis examines the value and impact of
68Ga-PSMA ligand PET/CT for the radiotherapeutic manage-
ment of prostate cancer patients. We presented a cohort of 57
patients both in the setting of primary diagnosis and disease
relapse. With a percentage of 38.6 % intermediate-risk and
54.4 % high-risk constellations, this was a selected cohort
with high probability of metastatic disease—locoregional or
Fig. 1 Overview of the impact of PSMA staging results on radiotherapy
(RX). In light grey cases treatment was carried out as initially planned
based on conventional staging information, and in dark grey cases
radiotherapeutic management was changed in dose or target volume
Fig. 2 Example of the impact of PSMA imaging on radiotherapeutic
management at initial diagnosis of intermediate-risk prostate cancer. a
PSMA PET/CT with tracer uptake in a pararectal lymph node (SUVmax
3.1; arrow) which was not clearly pathological in conventional CT (b).
Accordingly the irradiation plan was changed with coverage of perirectal
space and a simultaneous boost to the lymph node (c: IMRT in 34
fractions with 51 Gy to lymphatic pathways, 76.5 Gy to the prostate
and 61.2 Gy to the pathological lymph node). d IMRT plan prior to
PSMA PET information without sufficient coverage of the pathological
lymph node
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distant. It is important to emphasize the characteristics
of this patient group before interpretations of the results
can be made. In addition, this work has inherent limi-
tations due to its retrospective nature: the follow-up of
this new approach of imaging and selective treatment is
too short to report outcome; due to the short follow-up,
additionally applied androgen deprivation, which was
given to all lymph node-positive patients for at least
2 years; and the lack of a control group.
Today, exact data on sensitivity and specificity of PSMA-
11 PET/CT are still limited. However, PSMA-11 PET corre-
lated well with the histological findings in succeeding surgery
in 42 patients that have been recently published [24] and
is more sensitive than CT based 3D volumetric lymph node
evaluation in determining the node status of patients with re-
current prostate cancer [25]. A total of 319 patients have been
evaluated with follow-up as standard of reference and
sensitivity/specificity was reported with 76.6/100 %; the neg-
ative predictive value (NPV) and positive predictive value
(PPV) were 91.4 and 100 % [24]. Especially the high PPV
provides a good rationale to administer local radiation boosts
to PET-positive lymph nodes. Our report clearly demonstrates
the potential role of this method that can enable selective and
custom-tailored radiotherapy for patients with prostate cancer.
Today, radiotherapy techniques can perform these selective
dose escalations of tumour-bearing parts of the prostate or
metastatic lymph nodes [5, 6]. With the development of
intensity-modulated radiotherapy (IMRT), new possibilities
have been opened up for the treatment of prostate cancer.
Using a simultaneous integrated boost (SIB) concept, many
centres treat the whole pelvis in high-risk patients and apply a
SIB to the prostate or prostate bed [20]. Some groups have
taken this concept further and have used the SIB technique for
dose escalation to macroscopic lymph node metastases:
Fonteyne et al. [21] reported on 80 patients with T1–4 N1
M0 prostate cancer who received androgen deprivation for
2–3 years and whole-pelvis radiotherapy (45 Gy) and a SIB
to the prostate (69.3 Gy), to the intraprostatic lesion (72 Gy)
and to enlarged pelvic lymph nodes (65 Gy) in 25 fractions.
Radiotherapy was tolerated well with 3-year rates of late gas-
trointestinal toxicity of 8 % (grade 3) and 20 % (grade 3) and
late genitourinary toxicity of 6 % (grade 3–4) and 34% (grade
2). Actuarial 3-year biochemical recurrence-free survival was
81 %. Engels et al. [22] treated 28 high-risk patients with
whole-pelvis radiotherapy (54 Gy) with a SIB to the prostate
(70.5 Gy) in 30 fractions. Among these, macroscopic lymph
node metastases received a SIB (60 Gy) in eight patients. Acute
toxicity rates were low, and no difference in toxicity was seen
between patients with and without lymph node boost.
An Italian publication [23] described high-dose
hypofractionated IMRT treatment with SIB to pathological
nodes in 83 patients with a lymph node recurrence after
Fig. 3 Prostate cancer recurrence in the intermediate-risk situation. a, b
PSMA PET/CT with a pathological presacral lymph node that was
unclear in conventional CT (c). The corresponding IMRT plan is shown
in dwith 34 fractions and 51 Gy to the lymphatic pathways (arrow) and a
simultaneous integrated boost to the lymph node to 61.2 Gy. For
comparison e displays the IMRT plan without PET information
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primary treatment which was detected by 11C-choline PET/
CT. The treatment was tolerated well with only patients
experiencing acute grade 3 genitourinary side effects, and in
83 % of patients, a complete or partial biochemical response
was achieved [24].
The results of these approaches still have to be shown with
longer follow-up in controlled trials. Yet, the toxicity of such
individualized approaches reported so far is very promising
[26]. The key to this method, however, is a reliable, sensitive
and specific diagnostic tool.
In comparison to other diagnostic options, our results com-
pare favourably with those reported for 11C-choline PET in a
similar setting. Jereczek-Fossa reported a ratio of 22 of 74 cases
when 11C-choline PET/CTaltered the treatment approach com-
pared with the treatment that would have been adopted in the
absence of 11C-choline PET/CT analysis [11]. However, a new
technology can also introduce now pitfalls. In regard to PSMA
PET, physiological uptake in coeliac ganglia which could be
mistaken as M1a should carefully be considered [27].
Geiger et al. reported that 51 % of patients with non-small
cell lung cancer (NSCLC) had new findings in 18F-
fluorodeoxyglucose (FDG) PET/CT [28]. In a prospec-
tive study incorporating 18F-FDG PET/CT for stage III
NSCLC a probability of 54 % of changes of target
volumes was reported [29]. For these reasons this
PET/CT method is in routine use for NSCLC patients.
Our results suggest a similar impact of PSMA-11 PET/
CT staging for prostate cancer patients compared to 18F-
FDG PET/CT at least in this selected risk group. If
these findings can be reproduced in a prospective set-
ting, the method has the potential to become a routine
tool in the staging and therapy planning for prostate
cancer patients.
Among the PSMA PET-negative patients were many pa-
tients with a PSA <1 ng/ml. This underlines that for particular
patients with a low level of PSA the likelihood of detecting a
PSMA-positive lesion is smaller. However, even with a PSA
below 1 ng/ml the rate of positive PSMA PETwas described
to be around 50 % [24]. Furthermore, it has to be considered
that PET resolution also has its physical limitation and there-
fore might also bring a further limitation to lesion detection
even in a patient with PSMA-positive expression.
Fig. 4 Example of PSA relapse 3 years after prostatectomy and prostate
bed irradiation for high-risk prostate cancer. Only the PSMA PET/CT (a)
reveals the iliac lymph node metastases with an SUVmax of 9.7, whereas
the conventional CT (b) could show nothing. The corresponding IMRT
plan is shown in c with 26 fractions to the pelvic lymphatic pathways to
46.8 Gy and a simultaneous integrated boost to the lymph node to a dose
of 57.2 Gy. After prostate bed irradiation 3 years before radiotherapy
would not have been possible without the PET information
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Conclusion
PSMA-11 PET/CT had a significant impact on the manage-
ment of the presented cohort of radiotherapy patients with
prostate cancer. Radiotherapeutic management was changed
in 50.8 %. The treatment of lymph node areas in the pelvis has
already become more individualized by the use of IMRT. Ra-
diotherapy today delivers selective pelvic lymphatic irradia-
tion rather than standardized whole-pelvis irradiation. More
sensitive and specific staging helps to exclude stage IV pa-
tients from this approach and enables individualized dose es-
calation to lymph node metastases or subvolumes of the pros-
tate. The consequences in terms of changes for progression-
free survival and overall survival remain to be investigated.
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